Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) is a global company in analytical and clinical laboratory technologies, and its news flow reflects activity across life sciences, diagnostics, and applied markets. Company announcements highlight how Agilent’s instruments, software, services, and expertise are used to help customers bring great science to life, as well as how it manages its financial performance and corporate governance.
On this page, readers can follow Agilent news related to earnings results, product introductions, regulatory-focused solutions, capital allocation, and investor events. Recent releases include quarterly and full-year financial results, with details on revenue, net income, and segment performance for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These updates often include management commentary on business conditions and outlook.
Agilent’s news also covers product and technology developments. For example, the company has announced 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system, designed to support use in GMP-regulated manufacturing and quality control environments by adding secure user authentication, electronic signatures, and audit trails. Another announcement introduced Agilent Altura Ultra Inert HPLC Columns, described as high performance liquid chromatography columns suited for biotherapeutics applications such as peptide GLP-1 and oligonucleotide therapeutic development and quality control.
Investors and analysts can also find updates on capital markets activities, such as cash dividend declarations on Agilent’s common stock, and notices of participation in healthcare and investor conferences. Governance-related news, including leadership transitions and executive appointments, is communicated through press releases and related SEC filings. Bookmarking this page allows users to review Agilent’s ongoing communications about its operations, technologies, financial performance, and corporate developments in one place.
Agilent Technologies Inc. (NYSE: A) has been recognized as the 2022 Company of the Year by the Instrument Business Outlook (IBO), highlighting significant revenue growth, operational profit, and net income increases due to strategic growth initiatives. Innovations such as the HydroInert source and acquisitions including Virtual Control expand Agilent's capabilities, particularly in artificial intelligence and molecular analysis. The company also emphasizes its commitment to sustainability, pledging net-zero greenhouse gas emissions by 2050. Agilent generated $6.85 billion in revenue for fiscal 2022 and continues to enhance its product offerings.
Axion BioSystems has strongly rejected allegations from Agilent Technologies (NYSE: A) regarding patent infringement and false advertising related to its live-cell analysis products. Axion asserts that it does not infringe Agilent's patents and believes these claims are without merit. The company stands by its innovative technology and is prepared to defend its rights in court, anticipating a successful outcome. Axion emphasizes its commitment to advancing live-cell analysis tools to accelerate biomedical research and maintain its position as a market innovator.
Agilent Technologies (NYSE: A) announced a comprehensive end-to-end digital pathology solution that integrates advanced products from Visiopharm, Proscia, and Hamamatsu. This launch aims to enhance diagnostic quality while addressing the growing demand for improved patient care due to the rise in chronic conditions. The collaboration, expanding from Europe to the US and Canada, leverages AI-driven precision pathology software combined with automated staining solutions. The announcement coincides with the USCAP 112th Annual Meeting in New Orleans. Agilent aims to empower pathologists through efficient and innovative diagnostics, ultimately advancing personalized medicine.
Agilent Technologies (NYSE: A) has partnered with Hamamatsu Photonics to enhance its end-to-end digital pathology solution. This collaboration integrates Hamamatsu's NanoZoomer S360MD Slide scanner, which converts glass slides into high-resolution digital data, aiming to improve workflow efficiency in pathology laboratories. As pathologists face increased patient loads and remote work challenges, this advanced digital pathology platform intends to facilitate faster diagnostics and better patient outcomes. The partnership reflects Agilent's commitment to advancing precision medicine and supports the growing trend of digital pathology adoption.
Summary not available.
Agilent Technologies Inc. (NYSE: A) has acquired e-MSion, enhancing access to its innovative electron capture dissociation (ECD) technology, the ExD cell, for biopharma researchers globally. This compact device improves the assessment of complex biomolecules, allowing for faster therapeutic development. Agilent aims to integrate the ExD cell into its existing workflows and increase the reach of this technology, which enhances characterization of larger proteins. The acquisition aligns with Agilent's strategy to grow its biopharma solutions, which generated $6.85 billion in revenue for fiscal 2022.
Agilent Technologies Inc. (NYSE: A) announced a multi-year distribution agreement with Proscia to provide a comprehensive digital diagnostic pathology system. This collaboration combines Agilent's pathology staining solutions with Proscia's Concentriq® Dx platform, aiming to enhance efficiency and quality in pathology labs. Digital pathology adoption is driven by the need for precision medicine amidst a pathologist shortage. The open Concentriq Dx platform supports integration with existing lab technologies and is designed to meet future needs. This agreement emphasizes Agilent's commitment to improving patient health outcomes through innovative solutions.
Agilent Technologies Inc. (NYSE: A) has announced that its Chief Financial Officer, Bob McMahon, will participate in a Q&A session at the Barclays Global Healthcare Conference in Miami Beach, Florida, on March 15 at 3:05 p.m. EST. The event can be accessed via a webcast on the Agilent Investor Relations website, with a replay available for 90 days after the event.
Agilent, a leader in life sciences and diagnostics, reported $6.85 billion in revenue for fiscal 2022 and employs 18,000 people globally. More information can be found at www.agilent.com.
Agilent Technologies Inc. (NYSE: A) reported a strong start to 2023, with first-quarter revenue of $1.76 billion, marking a 5% year-over-year increase and 10% growth on a core basis. GAAP net income reached $352 million, an EPS of $1.19, up 28% from Q1 2022. Non-GAAP net income was $406 million, resulting in an EPS of $1.37, a 13% increase. The full-year revenue guidance has been raised to $7.03 billion to $7.10 billion, with anticipated growth of 2.7% to 3.7%.
Second-quarter revenue is projected between $1.655 billion and $1.680 billion, with non-GAAP EPS expected at $1.24 to $1.27.
Agilent Technologies Inc. (NYSE: A) has launched an on-deck thermal cycler (ODTC) accessory for its Bravo NGS automated liquid handling platform. This addition enhances the NGS sample preparation workflow by integrating thermal cycling into automated protocols. It significantly increases 'walk-away' time, allowing lab operators to focus on higher-level tasks. The ODTC is designed for use in various applications such as library preparation and target enrichment steps in NGS workflows. Agilent generated $6.85 billion in revenue in fiscal 2022 and continues to prioritize flexibility and productivity in lab settings.